(Q47228689)

12 January 2018

meta-analysis

0 references

title

Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction (English)

1 reference

12 January 2018

main subject

myocardial infarction

1 reference

Cohen M

1

1 reference

12 January 2018

Antman EM

2

1 reference

12 January 2018

Gurfinkel E

3

1 reference

12 January 2018

Turpie AG

4

1 reference

12 January 2018

Furst J

5

1 reference

12 January 2018

Bigonzi F

6

1 reference

12 January 2018

Radley D

7

1 reference

12 January 2018

language of work or name

English

0 references

publication date

1 September 2000

1 reference

12 January 2018

American Journal of Cardiology

published in

1 reference

12 January 2018

volume

86

1 reference

12 January 2018

issue

5

1 reference

12 January 2018

page(s)

553-6, A9

1 reference

12 January 2018

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

Delayed hospital presentation in patients who have had acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901014-6

10.1016/S0002-9149(00)01014-6

7 January 2021

Identifiers

DOI

1 reference

12 January 2018

1 reference

12 January 2018